• AAPL 194.0934
  • TSLA 241.4252
  • AMZN 146.495
  • BTC-USD 43155.6641
  • ETH-USD 2343.4756
  • EURUSD 1.0798
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. IMTX.US

Immatics NV (IMTX NASDAQ) stock market data APIs

$9.14 0.07(0.8%) as of December 6, 2023

Immatics NV Financial Data Overview

9.07
9.14
-
9.365
9.03
5.9-13.14
782 M
84 656 K
75 724 K
-0.32
0
0.619
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'IMTX',
Type: 'Common Stock',
Name: 'Immatics NV',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00VTL2H76',
ISIN: 'NL0015285941',
CUSIP: NULL,
CIK: '1809196',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2020-07-02',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
GicSector: 'Health Care',
GicGroup: 'Pharmaceuticals, Biotechnology & Life Sciences',
GicIndustry: 'Biotechnology',
GicSubIndustry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Immatics NV Fundamental Data is available in our Financial Data APIs

  • Net Revenue 75 724 K
  • EBITDA -70 563 000
  • Earnings Per Share -1.22
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Immatics NV Earnings via APIs

  • Latest Release 2023-11-14
  • EPS/Forecast -0.36

Get Immatics NV End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Immatics NV latest news via APIs

Levicept Appoints Eliot Forster as CEO

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) ...
  • DIRECTORS AND OFFICERS
  • LEVICEPT
  • MANAGEMENT CHANGES

Levicept Appoints Eliot Forster as CEO

Levicept Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NE...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com